Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

Black Hawk Acquisition Corporation Rights

BKHAR
$1.39 (+ $0.00 + 0.00%)
Last updated: Previous Close (2026-05-18)
BKHAR Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
Sector N/A
Industry N/A
ISINN/A
Market Price1.39
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend Frequency N/A
P/E RatioN/A
EPSN/A
Market Cap$2.5M
Book Value-0.8
Price to Book-2.265
Beta0.97
52w High1.81
52w Low1.81
Next Earnings DateN/A
About the Company
Black Hawk Acquisition Corp Rights are a type of financial instrument typically associated with a special purpose acquisition company (SPAC). These rights are issued to investors as part of the SPAC's initial public offering or in conjunction with private placements. Their primary function is to provide the holder with the opportunity to receive shares of the company upon certain conditions being met, generally the completion of a business merger or acquisition by the SPAC. These rights are particularly notable in the financial market for their role in speculative activities associated with SPACs, where investors seek to profit from the potential success of a proposed merger. Once a SPAC finds a suitable company to acquire, these rights may convert into shares of the combined entity, potentially offering value to the rights' holder once the merger is finalized. In the market ecosystem, Black Hawk Acquisition Corp Rights serve as a strategic tool for investors interested in participation in the fast-growing sector of SPAC mergers and acquisitions. They exemplify the innovative and complex financial instruments developed to meet the evolving needs of modern capital markets.
Price History
Latest News for BKHAR
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (Nasdaq: BKHA, BKHAU, BKHAR), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader wi
Black Hawk Acquisition Corporation Amends Its Definitive Proxy Statement
DANVILLE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Black Hawk Acquisition Corporation (NASDAQ: BKHAU, the “Company”) announced today that it filed a supplement to its definitive proxy statement, originally filed with the Securities and Exchange Commission on June 10, 2025, to amend the language of the Trust Amendment Proposal. Originally, the Trust Amendment Proposal provided that the Company would deposit into the trust account an amount equal to $0.033 multiplied by the number of ordinary sha
Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles
Transaction Values Vesicor at a Pre-money Equity Value of $70 millionBusiness Combination is Expected to be Completed in the Fourth Quarter of 2025 DANVILLE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Black Hawk Acquisition Corp. (Nasdaq: BKHAU, BKHA, BKHAR), a special purpose acquisition company, (“Black Hawk”) announced the signing of a Business Combination Agreement (“BCA”) on April 26, 2025, with Vesicor Therapeutics, Inc. (“Vesicor”, “Vesicor Therapeutics” or “the Company”), a California-ba